Cargando…

The Benefits and Risks of New Therapies for Type 2 Diabetes

Detalles Bibliográficos
Autores principales:	Asche, Car V., Nelson, Richard E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2008
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438152/ https://www.ncbi.nlm.nih.gov/pubmed/18774876 http://dx.doi.org/10.18553/jmcp.2008.14.7.655

Ejemplares similares

Targeting Hepatic Glucokinase in Type 2 Diabetes: Weighing the Benefits and Risks
por: Agius, Loranne
Publicado: (2009)

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
por: Drucker, Daniel J., et al.
Publicado: (2010)

Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
por: Longo, Miriam, et al.
Publicado: (2020)

Opinions Regarding the Value and Use of the AMCP Format Still Unknown
por: Asche, Carl V.
Publicado: (2007)

Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease
por: Shehadeh, Naim, et al.
Publicado: (2018)

The residual cardiorenal risk in type 2 diabetes
por: Giugliano, Dario, et al.
Publicado: (2021)

New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?
por: Popovic, Djordje S., et al.
Publicado: (2021)

Microalbuminuria and diabetic retinopathy in type 2 diabetic patients: From risk association to risk prediction
por: Chang, Chia‐Hsuin, et al.
Publicado: (2013)

Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
por: McGuire, Darren K., et al.
Publicado: (2021)

Targeting β‐cell functions in therapy for type 2 diabetes
por: Fujimoto, Shimpei, et al.
Publicado: (2011)

A roadmap to medical nutrition therapy in type 2 diabetes
por: Shalit, Almog, et al.
Publicado: (2023)

How can we realise the potentially large public health benefit of screening for type 2 diabetes mellitus in south Asians?
por: Stronks, K., et al.
Publicado: (2011)

Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
por: Cho, Young Min
Publicado: (2022)

Risk‐benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes
por: Chan, Juliana CN
Publicado: (2013)

Mortality Risk in Long-Standing Type 1 Diabetes: Hope and Concern
por: Hamman, Richard F.
Publicado: (2010)

Is Estradiol a Biomarker of Type 2 Diabetes Risk in Postmenopausal Women?
por: Mauvais-Jarvis, Franck
Publicado: (2017)

Induction of Heat Shock Proteins in the Therapy of Type 2 Diabetes and Metabolic Syndrome
por: Hooper, Philip L.
Publicado: (2014)

A New Activator of Hepatocyte CaMKII in Fasting and Type 2 Diabetes
por: Ozcan, Lale, et al.
Publicado: (2018)

Advances in Risk Prediction of Type 2 Diabetes: Integrating Genetic Scores With Framingham Risk Models
por: Keating, Brendan J.
Publicado: (2015)

X-Ray Imaging is Essential for Contemporary Chiropractic and Manual Therapy Spinal Rehabilitation: Radiography Increases Benefits and Reduces Risks
por: Oakley, Paul A., et al.
Publicado: (2018)

New national Biobank of The Danish Center for Strategic Research on Type 2 Diabetes (DD2)
por: Christensen, Henry, et al.
Publicado: (2012)

Attenuated Sympathoadrenal Responses, but Not Severe Hypoglycemia, During Aggressive Glycemic Therapy of Early Type 2 Diabetes
por: Amiel, Stephanie A., et al.
Publicado: (2009)

Benefits of aerobic exercise in myotonic dystrophy type 1
por: Mackenzie, Samuel J., et al.
Publicado: (2022)

The importance of improving health literacy to lower cardiovascular risk in type 2 diabetes
por: Hansen, Dominique, et al.
Publicado: (2019)

Statin discontinuation: counterbalancing the benefits with the potential risks
por: Paraskevas, Kosmas I., et al.
Publicado: (2011)

Vaccinations: Mandatory or Voluntary? Risk–Benefit Analysis
por: Socol, Yehoshua, et al.
Publicado: (2020)

“Prediction Is Very Hard, Especially About the Future”: New Biomarkers for Type 2 Diabetes?
por: Lowe, William L., et al.
Publicado: (2013)

T helper 17 cells: A new actor on the stage of type 2 diabetes and aging?
por: Chang, Yi‐Cheng, et al.
Publicado: (2021)

Maximizing the benefits of antiretroviral therapy for key affected populations
por: Grubb, Ian R, et al.
Publicado: (2014)

Tackling Cardiovascular Risk in Type 2 Diabetes: Does Baseline Glucose Control Matter?
por: Nicholls, Stephen J., et al.
Publicado: (2018)

Socioeconomic Disparities Across the Spectrum of Genetic Burden in Type 2 Diabetes and Obesity Risk
por: Franks, Paul W.
Publicado: (2023)

Repair of Damaged Pancreatic β Cells: New Hope for a Type 2 Diabetes Reversal?
por: Wang, Zhili, et al.
Publicado: (2021)

Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes
por: de Boer, Ian H., et al.
Publicado: (2018)

Pesticide Testing on Human Subjects: Weighing Benefits and Risks
por: Resnik, David B., et al.
Publicado: (2005)

Risks and benefits of transfusion for children with severe anemia in Africa
por: Brick, Thomas, et al.
Publicado: (2014)

Favourable Changes of the Risk-Benefit Ratio in Alpine Skiing
por: Burtscher, Martin, et al.
Publicado: (2015)

Genetic Risk for Lung Cancer and the Benefits of Quitting Smoking
por: Hall, F. Scott
Publicado: (2016)

A brief analysis and hypotheses about the risk of COVID-19 for people with type 1 and type 2 diabetes mellitus
por: Milionis, Charalampos, et al.
Publicado: (2020)

Health Insurance for Diabetes Prevention Confers Health Benefits and Breaks Even on Cost Within 2 Years
por: Weber, Mary Beth, et al.
Publicado: (2019)

Insulin Resistance and Type 2 Diabetes
por: Taylor, Roy
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ouppr2bds35jvmhtq9uvnmo269